Skip to main content
. Author manuscript; available in PMC: 2020 Mar 10.
Published in final edited form as: Oncogene. 2018 May 3;37(32):4428–4442. doi: 10.1038/s41388-018-0263-7

Figure 5. Stromal CXCL12 regulates angiogenesis and blood vessel permeability.

Figure 5

(A) Representative pictures of f/f;PyT and Δ/Δ;PyT tumor sections stained with endothelial cell-specific CD31 antibody. Scale bar, 100μm.

(B) Quantification of vascular density in tumors as determined by the number of CD31+ blood vessels (from A) per 20× field.

(C) Quantification of CD31+/Sca1+ cells in tumors as determined by flow cytometry.

(D) Confocal images of tumors from mice injected with Fluorescent-dextran (F-dextran; 2000KD, FITC conjugated). Scale bar, 100μm. Side panels represent higher magnification of single blood vessels. Scale bar 50μm.

(E) Quantification of mean blood vessel diameter determined from images in (D).

(F) The trans-edothelial migration of MVT-1 cells was analyzed by using matrigel coated transwells and MEECs in the presence or absence of CAFs isolated from f/f;PyT and Δ/Δ;PyT tumors. The trsanswells with f/f;PyT and Δ/Δ;PyT were treated with AMD-3100 (AMD) and recombinant CXCL12 (rCXCL12) respectively. *, p<0.05; **, p<0.01; ***, p< 0.001. One-way anova t-test.